AI Article Synopsis
- Ixekizumab (IXE) is a monoclonal antibody that targets interleukin-17A and is approved for treating moderate to severe plaque psoriasis in children in the US and EU.
- The review focuses on the findings from the phase 3 IXORA-PEDS trial, which included randomized, double-blind, placebo-controlled studies, alongside insights gained from three years of clinical experience with IXE.
- IXE is currently the only IL-17 antagonist available for pediatric psoriasis, marking a significant advancement in treatment options for this demographic.
Article Abstract
: Ixekizumab (IXE), a high affinity humanized monoclonal antibody that selectively targets interleukin-17A, is approved in the United States (US) and the European Union (EU) for pediatric patients with moderate to severe plaque psoriasis. This review summarizes ixekizumab use in the phase 3, randomized, double-blind, placebo-controlled study in pediatric patients with moderate to severe plaque psoriasis and provides some clinical pearls we have learned after using the drug in the pediatric population for the past 3 years.: Review of IXORA-PEDS trial data, general literature review pertaining to the systemic treatment of pediatric psoriasis as well as our clinical experience with IXE: IXE is the only IL17 antagonist for pediatric psoriasis and is a welcome addition to our armamentarium.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14712598.2021.1931679 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!